Literature DB >> 19504554

Routes, dynamics, and correlates of cochlear inflammation in terminal and recovering experimental meningitis.

Per Cayé-Thomasen1, Lise Worsøe, Christian Thomas Brandt, Hidemi Miyazaki, Christian Ostergaard, Niels Frimodt-Møller, Jens Thomsen.   

Abstract

OBJECTIVES/HYPOTHESIS: To examine the routes, dynamics and correlates of cochlear inflammation in meningitis to provide information on the pathogenesis of the associated hearing loss and indications for rational pharmacotherapeutical intervention. STUDY
DESIGN: A well-established rat model of Streptococcus pneumoniae meningitis was employed.
METHODS: Eight rats were inoculated intrathecally and not treated, whereas 26 were inoculated and treated with ceftriaxone. Six rats were sham-inoculated, making a total of 40 rats. The rats were sacrificed when reaching terminal illness or after 7 days, followed by light microscopy. Routes of cochlear inflammatory infiltration were examined. The volume fraction of inflammatory infiltration was estimated and correlated to bacterial and leukocyte counts in cerebrospinal fluid (CSF) and blood.
RESULTS: The perilymphatic space was infiltrated with inflammatory cells via cochlear aqueduct, whereas the endolymphatic space was infiltrated from the spiral ligament. Rosenthal's canal was infiltrated through osseous spiral lamina canaliculi. In the untreated group, the degree of inflammation correlated with time of death, whereas antibiotic treatment reversed this development. Perilymphatic inflammation correlated significantly with the CSF leukocyte count, whereas endolymphatic inflammation correlated with spiral ligament inflammation.
CONCLUSIONS: Meningogenic inflammation of the rat cochlea occurs via the cochlear aqueduct and the spiral ligament capillary bed. The spiral ganglion is infiltrated through the osseous spiral lamina. The degree of inflammation correlates positively with time of death in untreated meningitis, whereas antibiotic treatment leads to subsiding infiltration during recovery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504554     DOI: 10.1002/lary.20260

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Endolymphatic sac involvement in bacterial meningitis.

Authors:  Martin Nue Møller; Christian Brandt; Christian Østergaard; Per Caye-Thomasen
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-23       Impact factor: 2.503

2.  Characterisation of cochlear inflammation in mice following acute and chronic noise exposure.

Authors:  Winston J T Tan; Peter R Thorne; Srdjan M Vlajkovic
Journal:  Histochem Cell Biol       Date:  2016-04-25       Impact factor: 4.304

3.  Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection.

Authors:  Nadezhda E Yun; Shannon Ronca; Atsushi Tamura; Takaaki Koma; Alexey V Seregin; Kelly T Dineley; Milagros Miller; Rebecca Cook; Naoki Shimizu; Aida G Walker; Jeanon N Smith; Joseph N Fair; Nadia Wauquier; Bayon Bockarie; Sheik Humarr Khan; Tomoko Makishima; Slobodan Paessler
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

4.  Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis.

Authors:  Tobias Högen; Cornelia Demel; Armin Giese; Barbara Angele; Hans-Walter Pfister; Uwe Koedel; Matthias Klein
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

5.  Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis.

Authors:  Cornelia Demel; Tobias Hoegen; Armin Giese; Barbara Angele; Hans-Walter Pfister; Uwe Koedel; Matthias Klein
Journal:  J Neuroinflammation       Date:  2011-01-24       Impact factor: 8.322

Review 6.  Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss.

Authors:  Gilda M Kalinec; Gwen Lomberk; Raul A Urrutia; Federico Kalinec
Journal:  Front Cell Neurosci       Date:  2017-07-07       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.